Results 11 to 20 of about 18,729 (264)

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. [PDF]

Hypertension, 2020
Supplemental Digital Content is available in the text. This study examined the dose-response characteristics of aprocitentan, a dual endothelin A/endothelin B receptor antagonist, in patients with essential hypertension.
Verweij P, Danaietash P, Flamion B, Ménard J, Bellet M.   +4 more
europepmc   +2 more sources

The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial. [PDF]

J Am Soc Nephrol
Visual Abstract Key Points Patients with IgA nephropathy and significant proteinuria are at high risk of progressive kidney function loss and kidney failure. We report the results of a clinical trial assessing the selective endothelin receptor antagonist
Heerspink HJL, Du X, Xu Y, Zhang Y, Liu B, Bi G, Xu C, Luo Q, Wu H, Wan J, Cao L, Wang R, Fan Q, Cheng H, Xu L, Huang J, Zhong A, Peng Q, Hei Y, Wang Y, Zhou B, Zhang L, Chen J.   +22 more
europepmc   +2 more sources

Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. [PDF]

Clin Pharmacokinet, 2015
Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vascular system, which leads to right-sided heart failure and ultimately death if untreated. Treatments to regulate the pulmonary vascular pressure target the prostacyclin, nitric
Sidharta PN, Treiber A, Dingemanse J.
europepmc   +2 more sources

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.

Kidney International, 2020
The diuretic effects achieved with sodium glucose co-transporter 2 inhibitors (SGLT2i) may offset fluid retaining effects of the endothelin receptor antagonist (ERA) atrasentan while effects on albuminuria and kidney protection of both drug classes may ...
H. Heerspink, D. Kohan, D. de Zeeuw
semanticscholar   +1 more source

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. [PDF]

PLoS ONE, 2012
Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and ...
John Gatfield, Celia Mueller Grandjean, Thomas Sasse, Martine Clozel, Oliver Nayler   +4 more
doaj   +1 more source

Endothelin Receptors and Their Antagonists

Seminars in Nephrology, 2015
All three members of the endothelin (ET) family of peptides, ET-1, ET-2, and ET-3, are expressed in the human kidney, with ET-1 being the predominant isoform. ET-1 and ET-2 bind to two G-protein-coupled receptors, ETA and ETB, whereas at physiological concentrations ET-3 has little affinity for the ET(A) receptor.
Maguire, Janet J, Davenport, Anthony P
openaire   +3 more sources

The Effect of Endothelin-1 on Gene Expression of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase via Transforming Growth Factor Beta (TGF–β) Receptor in Human Aortic Smooth Muscle Cells

مجله دانشکده پزشکی اصفهان, 2018
Background: Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) is one of the predominant sources of the production of free oxygen radicals in the vascular wall.
Parisa Dayati, Reyhaneh Niayesh-Mehr, Alireza Jafari, Hossein Babaahmadi-Rezaei   +3 more
doaj   +1 more source

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension

Respiratory Research, 2011
Background Endothelin-1 signalling plays an important role in pathogenesis of pulmonary hypertension. Although different endothelin-A receptor antagonists are developed, a novel therapeutic option to cure the disease is still needed.
Brandes Ralf P, Janssen Wiebke, Cornitescu Teodora, Sydykov Akylbek, Dahal Bhola K, Luitel Himal, Kojonazarov Baktybek, Kosanovic Djuro, Davie Neil, Ghofrani Hossein A, Weissmann Norbert, Grimminger Friedrich, Seeger Werner, Schermuly Ralph T   +13 more
doaj   +1 more source

Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis

Pulmonary Circulation, 2020
Limited evidence is available on outcomes associated with currently available medications from the endothelin receptor antagonist drug class (bosentan, ambrisentan, and macitentan) in elderly patients with pulmonary arterial hypertension.
Raymond L. Benza, Cassandra A. Lickert, Lin Xie, William Drake, Adesuwa Ogbomo, Huseyin Yuce, Michele R. Cole   +6 more
doaj   +1 more source

EGF Receptor Transactivation by Endothelin-1 Increased CHSY-1 Mediated by NADPH Oxidase and Phosphorylation of ERK1/2 [PDF]

Cell Journal, 2021
Objective: Growth factors [transforming growth factor-β (TGF-β), epidermal growth factor (EGF), endothelin-1 (ET-1)] stimulate proteoglycan synthesis resulting in retention and accumulation of low density lipoprotein (LDL) in vessel intima and leading to
Hossein Babaahmadi-Rezaei, Alireza Kheirollah, Mojtaba Rashidi, Faezeh Seif, Zahra Niknam, Masoumeh Zamanpour   +5 more
doaj   +1 more source